We compared the effectiveness of an educational intervention at reducing stigma and improving knowledge of human papillomavirus (HPV) and cervical cancer among Nigerian men and women. We used a pre-/posttest design to deliver 2 educational interventions to 266 adults. Low knowledge was observed at baseline, which improved significantly post-intervention with no difference between groups. No significant changes were observed between groups in 5 out the 6 stigma domains. Health education was effective in improving knowledge. However, the lack of positive change in stigma shows urgent need for HPV and cervical cancer stigma reduction interventions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/FCH.0000000000000309 | DOI Listing |
PLOS Glob Public Health
January 2025
Britain Nepal Medical Trust, United Kingdom of Great Britain and Northern Ireland (UK), London, United Kingdom.
Cervical cancer is the leading cancer among women in Nepal, but the country has very low screening rate, with only 8.2% of women being screened. In recent years, a self-sampling kit for testing for the human papillomavirus (HPV) has been developed to allow self-sampling and enable early detection of cervical abnormalities.
View Article and Find Full Text PDFJ Low Genit Tract Dis
January 2025
Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, MD.
Objective: The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of extended genotyping results in cervical cancer prevention programs.
Methods: Risks of cervical intraepithelial neoplasia grade 3 or worse were calculated using data obtained with the Onclarity HPV Assay from large cohorts. Management recommendations were based on clinical action thresholds developed for the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines.
Int J Oncol
February 2025
Department of Pathology, GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center, 6229HX Maastricht, The Netherlands.
Human papillomavirus (HPV)‑positive and -negative head and neck squamous cell carcinoma (HNSCC) are often associated with activation of the phosphatidylinositol 3‑kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway due to mutations or amplifications in , loss of or activation of receptor tyrosine kinases. In HPV‑negative tumors, (encoding p16 protein) inactivation or (encoding Cyclin D1 protein) amplification frequently results in sustained cyclin‑dependent kinase (CDK) 4/6 activation. The present study aimed to investigate the efficacy of the CDK4/6 inhibitors (CDKi) palbociclib and ribociclib, and the PI3K/Akt/mTOR pathway inhibitors (PI3Ki) gedatolisib, buparlisib and alpelisib, in suppressing cell viability of HPV‑positive and ‑negative HNSCC cell lines.
View Article and Find Full Text PDFCureus
December 2024
Department of Midwifery, University of West Attica, Athens, GRC.
Aim This study aimed to investigate women's knowledge and beliefs about cervical cancer and cervical smear examinations. Methodology The research was conducted at a health center in Greece from May 15, 2023, to August 15, 2023. The study sample consisted of 160 women aged 21-65 years who attended the health center.
View Article and Find Full Text PDFCureus
December 2024
Department of Community Medicine, Institute of Medical Sciences and Sum Hospital, Siksha 'O' Anusandhan, Bhubaneswar, IND.
Introduction Human papillomavirus (HPV) is the most common causative agent for cervical cancer (CC) in women. Despite extensive initiatives, the acceptance and implementation of vaccinations have remained inadequate, hindering a significant impact on public health outcomes. This study aimed to provide a comprehensive assessment of the knowledge, awareness, and practices (KAP) scores of medical and dental students regarding HPV infection and vaccination.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!